INDIVIOR PLC (INDV) Stock Fundamental Analysis
NASDAQ:INDV - Nasdaq - GB00BN4HT335 - Common Stock - Currency: USD
INDV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of INDV while its profitability can be described as average. INDV has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year INDV was profitable.
INDV had a positive operating cash flow in the past year.
In multiple years INDV reported negative net income over the last 5 years.
In multiple years INDV reported negative operating cash flow during the last 5 years.
1.2 Ratios
INDV has a better Return On Assets (-4.09%) than 77.27% of its industry peers.
INDV has a better Return On Invested Capital (108.94%) than 99.49% of its industry peers.
The Average Return On Invested Capital over the past 3 years for INDV is in line with the industry average of 41.77%.
The 3 year average ROIC (43.06%) for INDV is below the current ROIC(108.94%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.09% | ||
| ROE | N/A | ||
| ROIC | 108.94% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
1.3 Margins
In the last couple of years the Profit Margin of INDV has declined.
INDV's Operating Margin of 25.22% is amongst the best of the industry. INDV outperforms 90.91% of its industry peers.
In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
INDV has a better Gross Margin (84.02%) than 88.38% of its industry peers.
INDV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.22% | ||
| PM (TTM) | N/A | ||
| GM | 84.02% |
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
2. Health
2.1 Basic Checks
INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, INDV has less shares outstanding
The number of shares outstanding for INDV has been reduced compared to 5 years ago.
The debt/assets ratio for INDV is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.80 indicates that INDV is not a great score, but indicates only limited risk for bankruptcy at the moment.
INDV has a better Altman-Z score (2.80) than 75.25% of its industry peers.
INDV has a debt to FCF ratio of 66.60. This is a negative value and a sign of low solvency as INDV would need 66.60 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 66.60, INDV is doing good in the industry, outperforming 76.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 66.6 | ||
| Altman-Z | 2.8 |
ROIC/WACC10.71
WACC10.17%
2.3 Liquidity
A Current Ratio of 0.89 indicates that INDV may have some problems paying its short term obligations.
INDV has a worse Current ratio (0.89) than 85.35% of its industry peers.
INDV has a Quick Ratio of 0.89. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
INDV has a Quick ratio of 0.70. This is amonst the worse of the industry: INDV underperforms 86.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
The earnings per share for INDV have decreased strongly by -24.28% in the last year.
Measured over the past years, INDV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -29.07% on average per year.
Looking at the last year, INDV shows a small growth in Revenue. The Revenue has grown by 4.34% in the last year.
INDV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.53% yearly.
EPS 1Y (TTM)-24.28%
EPS 3Y-29.07%
EPS 5YN/A
EPS Q2Q%10.81%
Revenue 1Y (TTM)4.34%
Revenue growth 3Y-4.53%
Revenue growth 5YN/A
Sales Q2Q%-6.34%
3.2 Future
The Earnings Per Share is expected to decrease by -15.65% on average over the next years. This is quite bad
INDV is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -6.61% yearly.
EPS Next Y8.11%
EPS Next 2Y-1.39%
EPS Next 3Y-10.28%
EPS Next 5Y-15.65%
Revenue Next Year3.53%
Revenue Next 2Y-2.92%
Revenue Next 3Y-9.06%
Revenue Next 5Y-6.61%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 6.61 indicates a rather cheap valuation of INDV.
94.95% of the companies in the same industry are more expensive than INDV, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of INDV to the average of the S&P500 Index (28.79), we can say INDV is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.79, the valuation of INDV can be described as very cheap.
Based on the Price/Forward Earnings ratio, INDV is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.38. INDV is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 6.79 |
4.2 Price Multiples
INDV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INDV is cheaper than 97.47% of the companies in the same industry.
INDV's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. INDV is cheaper than 76.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 288.45 | ||
| EV/EBITDA | 2.45 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as INDV's earnings are expected to decrease with -10.28% in the coming years.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y-1.39%
EPS Next 3Y-10.28%
5. Dividend
5.1 Amount
No dividends for INDV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.56
+0.8 (+7.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners89.83%
Inst Owner Change0.07%
Ins Owners3.68%
Ins Owner ChangeN/A
Market Cap1.44B
Analysts82.5
Price Target15.4 (33.22%)
Short Float %2.12%
Short Ratio1.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.56%
PT rev (3m)-18.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-15.93%
EPS NY rev (3m)-25.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 6.79 | ||
| P/S | 0.69 | ||
| P/FCF | 288.45 | ||
| P/OCF | 40.06 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 2.45 |
EPS(TTM)1.75
EY15.14%
EPS(NY)1.7
Fwd EY14.72%
FCF(TTM)0.04
FCFY0.35%
OCF(TTM)0.29
OCFY2.5%
SpS16.66
BVpS-2.79
TBVpS-2.84
PEG (NY)0.81
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.09% | ||
| ROE | N/A | ||
| ROCE | 137.9% | ||
| ROIC | 108.94% | ||
| ROICexc | 689.93% | ||
| ROICexgc | 766.59% | ||
| OM | 25.22% | ||
| PM (TTM) | N/A | ||
| GM | 84.02% | ||
| FCFM | 0.24% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score5
Asset Turnover1.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 66.6 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 106.9% | ||
| Cap/Sales | 1.49% | ||
| Interest Coverage | 16.38 | ||
| Cash Conversion | 6.51% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 2.8 |
F-Score5
WACC10.17%
ROIC/WACC10.71
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.28%
EPS 3Y-29.07%
EPS 5YN/A
EPS Q2Q%10.81%
EPS Next Y8.11%
EPS Next 2Y-1.39%
EPS Next 3Y-10.28%
EPS Next 5Y-15.65%
Revenue 1Y (TTM)4.34%
Revenue growth 3Y-4.53%
Revenue growth 5YN/A
Sales Q2Q%-6.34%
Revenue Next Year3.53%
Revenue Next 2Y-2.92%
Revenue Next 3Y-9.06%
Revenue Next 5Y-6.61%
EBIT growth 1Y101.54%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year11.33%
EBIT Next 3Y10.91%
EBIT Next 5Y12.03%
FCF growth 1Y101.42%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y112%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%